NT-004 / NewGen Therapeutics - LARVOL DELTA

Circulating tumor DNA predicts clinical outcome in early stage triple negative breast cancer (SABCS 2017) - P2; "...Patients receive docetaxel and carboplatin every 3 weeks X 6 cycles...ctDNA also identifies recurrence following curative therapy. Evaluating ctDNA as a biomarker of outcome in TNBC is warranted."

Biomarker • Clinical • Triple Negative Breast Cancer

The effects of left dorsolateral prefrontal transcranial direct current stimulation on episodic future thinking following acute psychosocial stress. (PubMed, Memory) - "We did not observe an effect from active tDCS on cortisol AUCi, and equally there was no interaction effect between cortisol AUCi and stimulation condition predictive for EFT specificity. Although we did not find evidence for the effects of tDCS on the HPA-system, our data reveal a crucial link between two critical predictors of mental health for the first time, and provide a solution to help rehabilitate EFT deficits.Trial registration: Netherlands National Trial Register identifier: ntr004.."

Journal • CNS Disorders • Immunology